3 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod http://www.zacks.com/stock/news/432688/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod?cid=CS-ZC-FT-432688 Jun 21, 2019 - Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use http://www.zacks.com/stock/news/431009/astrazeneca-mercks-lynparza-wins-eu-nod-for-first-line-use?cid=CS-ZC-FT-431009 Jun 18, 2019 - AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
AstraZeneca Gives Detailed Data From Calquence Leukemia Study http://www.zacks.com/stock/news/430525/astrazeneca-gives-detailed-data-from-calquence-leukemia-study?cid=CS-ZC-FT-430525 Jun 17, 2019 - AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

Pages: 1

Page 1